Cranes Software International Receives BSE Approval For Listing of 4 Crore Warrant Shares

Cranes Software International Ltd's share capital will increase with the listing of 4,00,00,000 equity shares following BSE's approval for trading. These shares were converted from warrants allotted on a preferential basis to Promoter Director Mr. Asif Khader at ₹4.57 per share.
Reader Takeaway: Warrant conversion adds shares post-approval; low allotment price signals capital infusion needs.

What just happened (today’s filing)

Cranes Software International Limited has received official trading approval from the Bombay Stock Exchange (BSE) for the listing and trading of 4,00,00,000 equity shares. These shares were issued upon the conversion of warrants, allotted on a preferential basis. The recipient of these shares is Mr. Asif Khader, a Promoter Director, at an allotment price of ₹4.57 per share. The shares are effective for trading starting April 28, 2026.

The conversion and allotment process was based on a board meeting approval on December 9, 2025, following the receipt of the balance exercise payment for the warrants. The company confirmed it has completed the necessary formalities with the BSE for the trading approval.

Why this matters

This event signifies the completion of a preferential allotment process initiated earlier, leading to an increase in the company's issued and paid-up share capital. For shareholders, it means a larger equity base from which the company will operate going forward. It also marks a step towards restructuring or strengthening the company's capital structure.

The backstory (grounded)

The journey to this listing began with the in-principle approval for warrant allotment to Mr. Asif Khader on May 28, 2024, followed by the actual allotment of warrants on June 11, 2024. The company's promoter holding has historically been low, standing at approximately 4.64% as of March 2026. A 2023 notice had indicated a potential post-issue shareholding for Mr. Asif Khader to reach 21.36% upon full conversion of warrants, underscoring the significance of this current conversion for his stake.

What changes now

• The total number of equity shares of Cranes Software International Ltd will increase.
• This marks the finalisation of the preferential allotment of shares to the promoter director.
• The newly converted shares will be available for trading on the BSE from April 28, 2026.

Risks to watch

Analysts have recently issued strong warnings regarding Cranes Software International Ltd. In March 2026, MarketsMojo downgraded the stock to a 'Strong Sell' rating, citing deteriorating technicals, weak long-term fundamentals, and poor valuation metrics.

Key concerns include a negative book value, indicating liabilities exceeding assets, and a sharp decline in net sales by -20.0% over the last five years. The company also faces challenges with high debtor days of 262 and reported a consolidated loss for FY24. Liquidity is also a point of concern, with low cash and cash equivalents.

Peer comparison

Cranes Software International operates in the broader IT software sector, a space populated by larger players. Its peers include companies like Tata Consultancy Services Ltd., Infosys Ltd., HCL Technologies Ltd., and Wipro Ltd., which are significant entities in the Indian and global IT landscape. However, Cranes Software is a micro-cap company with distinct operational and financial characteristics compared to these larger peers.

Context metrics (time-bound)

• The company reported a consolidated loss from operations before tax of Rs. 4.76 crores for the financial year ended March 31, 2024.
• Net sales have declined at an annualised rate of -20.0% over the past five years (FY20-FY24).

What to track next

• Monitor the trading activity and price performance of the newly listed 4 crore equity shares.
• Observe any changes in the shareholding pattern following the conversion and listing.
• Track future financial results for signs of improvement in sales and profitability, addressing current concerns.
• Note any management commentary on the utilisation of capital infusion from warrant exercise.